GNQ Insilico enters collaboration with Fortune 100 tech firm for AI-driven drug discovery

IB Acquisition Corp.

GNQ Insilico signed a Joint Initiative Agreement with a Fortune 100 global technology company.
Collaboration combines GNQ's AI platforms with partner's consulting, cloud, and quantum computing.
Initial term of two years, global territory, non-exclusive, with option to extend.
Partnership aims to advance AI-driven drug discovery and precision medicine solutions.
Relates to proposed business combination between IB Acquisition Corp. (IBAC) and GNQ.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.